20
Cipla Ltd, based in India, is a pharmaceutical company that stands out with its certifications from FDA, EDQM and WHO-GMP.
One of their notable products is AMLODIPINE BESYLATE USP, with a corresponding US DMF Number 17032.
Remarkably, this DMF maintains an Active status since its submission on December 17, 2003, highlighting commitment to regulatory compliance.
Their GDUFA DMF Review was successfully complete, with a review date of March 17, 2017, and payment made on March 06, 2017, indicating their dedication to facilitating drug approvals, Categorized as Type II